Scott Lish Sells 19,900 Shares of Alphatec (NASDAQ:ATEC) Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) COO Scott Lish sold 19,900 shares of Alphatec stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $19.64, for a total transaction of $390,836.00. Following the sale, the chief operating officer owned 641,432 shares in the company, valued at approximately $12,597,724.48. This represents a 3.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Scott Lish also recently made the following trade(s):

• On Friday, December 5th, Scott Lish sold 10,875 shares of Alphatec stock. The stock was sold at an average price of $21.47, for a total transaction of $233,486.25.
• On Thursday, November 20th, Scott Lish sold 25,000 shares of Alphatec stock. The shares were sold at an average price of $19.80, for a total transaction of $495,000.00.

Alphatec Price Performance

NASDAQ ATEC traded up $0.30 on Thursday, reaching $19.87. 1,203,104 shares of the stock traded hands, compared to its average volume of 2,040,826. Alphatec Holdings, Inc. has a 12 month low of $8.70 and a 12 month high of $22.66. The company has a quick ratio of 1.24, a current ratio of 1.99 and a debt-to-equity ratio of 43.02. The firm’s fifty day simple moving average is $18.90 and its 200 day simple moving average is $15.29. The company has a market cap of $2.95 billion, a price-to-earnings ratio of -19.11 and a beta of 1.08.

Alphatec (NASDAQ:ATEC) last announced its earnings results on Thursday, October 30th. The medical technology company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.09. The firm had revenue of $196.50 million for the quarter, compared to the consensus estimate of $182.78 million. The company’s quarterly revenue was up 30.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.28) EPS. As a group, research analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Institutional Trading of Alphatec

Hedge funds have recently bought and sold shares of the stock. Aster Capital Management DIFC Ltd acquired a new stake in Alphatec in the 3rd quarter worth $34,000. Osterweis Capital Management Inc. bought a new stake in shares of Alphatec in the second quarter valued at about $37,000. Nisa Investment Advisors LLC increased its stake in Alphatec by 22.4% during the second quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock valued at $63,000 after acquiring an additional 1,045 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in Alphatec in the 3rd quarter valued at approximately $73,000. Finally, FNY Investment Advisers LLC bought a new stake in shares of Alphatec in the 3rd quarter worth approximately $74,000. 66.35% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ATEC. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alphatec in a research note on Monday. Piper Sandler restated an “overweight” rating and issued a $25.00 target price (up previously from $20.00) on shares of Alphatec in a report on Friday, October 31st. Wells Fargo & Company lifted their price target on Alphatec from $14.00 to $16.00 and gave the company an “overweight” rating in a report on Thursday, October 16th. Lake Street Capital set a $25.00 price target on Alphatec and gave the company a “buy” rating in a research note on Friday, October 31st. Finally, HC Wainwright raised their price objective on shares of Alphatec from $20.00 to $24.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.45.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.